JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

IQVIA Holdings Inc

Închisă

SectorSănătate

231.16 0.46

Rezumat

Modificarea prețului

24h

Curent

Minim

226.48

Maxim

231.72

Indicatori cheie

By Trading Economics

Venit

66M

332M

Vânzări

83M

4.1B

P/E

Medie Sector

32.889

90.422

Marjă de profit

8.098

Angajați

91,000

EBITDA

102M

883M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+14.06% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3B

41B

Deschiderea anterioară

230.7

Închiderea anterioară

231.16

Sentimentul știrilor

By Acuity

50%

50%

147 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

IQVIA Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb. 2026, 23:23 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb. 2026, 22:57 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb. 2026, 21:51 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 feb. 2026, 21:49 UTC

Câștiguri

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb. 2026, 21:39 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:36 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb. 2026, 21:34 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:28 UTC

Achiziții, Fuziuni, Preluări

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 21:23 UTC

Câștiguri

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb. 2026, 21:19 UTC

Câștiguri

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:10 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:08 UTC

Câștiguri

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb. 2026, 21:07 UTC

Câștiguri

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q EPS 24c >PLTR

2 feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparație

Modificare preț

IQVIA Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

14.06% sus

Prognoză pe 12 luni

Medie 262.5 USD  14.06%

Maxim 290 USD

Minim 230 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIQVIA Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

8

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

150.68 / 153.45Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

147 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat